Insulin and New Insulin Analogues with Focus on Type 2 Diabetes

  • Sten Madsbad

The underlying insulin resistance and impaired insulin secretion in patients with type 2 diabetes worsen over time, necessitating the use of antidiabetic drugs, often in combination, to control glycaemic levels [1]. From the UKPD study the main explanation for the progressive history of type 2 diabetes seems to be a failure of beta-cell function over time [2], while insulin resistance may be more constant from diagnosis [2]. Therefore, it is not surprising that insulin treatment is necessary in most patients 10–15 years after diagnosis to maintain of HbA1c level as close to normal as is safely possible [2]. A consensus recommendation for the treatment of type 2 diabetes has recently been published [1].


Human Insulin Insulin Glargine Basal Insulin Insulin Analogue Insulin Aspart 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49(8):1711–1721.CrossRefPubMedGoogle Scholar
  2. 2.
    Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281(21):2005–2012.CrossRefPubMedGoogle Scholar
  3. 3.
    Taylor R, Davies R, Fox C, Sampson M, Weaver JU, Wood L. Appropriate insulin regimes for type 2 diabetes: a multicenter randomized crossover study. Diabetes Care 2000;23(11):1612–1618.CrossRefPubMedGoogle Scholar
  4. 4.
    Chow CC, Tsang LW, Sorensen JP, Cockram CS. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995;18(3):307–314.CrossRefPubMedGoogle Scholar
  5. 5.
    Harris SB, Ekoe JM, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res Clin Pract 2005;70(1):90–97.CrossRefPubMedGoogle Scholar
  6. 6.
    Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984;7(2): 188–199.CrossRefPubMedGoogle Scholar
  7. 7.
    Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291(3): 335–342.CrossRefPubMedGoogle Scholar
  8. 8.
    Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002; 45(7): S23–S28.PubMedGoogle Scholar
  9. 9.
    Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327(20):1426–1433.PubMedCrossRefGoogle Scholar
  10. 10.
    Yki-Jarvinen H, Nikkila K, Makimattila S. Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus. Drugs 1999;58(Suppl. 1):53–54.CrossRefPubMedGoogle Scholar
  11. 11.
    Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 2006;7(3):325–343.CrossRefPubMedGoogle Scholar
  12. 12.
    Chatterjee S, Tringham JR, Davies MJ. Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus. Expert Opin Pharmacother 2006; 7(10):1357–1371.CrossRefPubMedGoogle Scholar
  13. 13.
    Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23(5):644–649.CrossRefPubMedGoogle Scholar
  14. 14.
    Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23(8):1130–1136.CrossRefPubMedGoogle Scholar
  15. 15.
    Rosenstock J, Schwartz SL, Clark CM, Jr., Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24(4):631–636.CrossRefPubMedGoogle Scholar
  16. 16.
    Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138(12):952–959.PubMedGoogle Scholar
  17. 17.
    Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26(11):3080–3086.CrossRefPubMedGoogle Scholar
  18. 18.
    Eliaschewitz FG, Calvo C, Valbuena H, Ruiz M, Aschner P, Villena J et al. Latin American clinical trial project on insulin glargine versus NPH insulin plus glimepiride in Type 2 diabetes. Diabetologia 2003;46:A272.Google Scholar
  19. 19.
    Massi BM, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003;35(3):189–196.CrossRefGoogle Scholar
  20. 20.
    Standl E, Maxeiner S, Raptis S, Karimi-Anderesi Z, Schweitzer MA. Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care 2005;28(2):419–420.CrossRefPubMedGoogle Scholar
  21. 21.
    Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49(3):442–451.CrossRefPubMedGoogle Scholar
  22. 22.
    Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28(2):254–259.CrossRefPubMedGoogle Scholar
  23. 23.
    Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28(2):260–265.CrossRefPubMedGoogle Scholar
  24. 24.
    Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004;26(12): 2034–2044.CrossRefPubMedGoogle Scholar
  25. 25.
    Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med 2005;22(4):374–381.CrossRefPubMedGoogle Scholar
  26. 26.
    Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28(4):950–955.CrossRefPubMedGoogle Scholar
  27. 27.
    Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995;312(Pt 3):725–731.PubMedGoogle Scholar
  28. 28.
    Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53(6):1614–1620.CrossRefPubMedGoogle Scholar
  29. 29.
    Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29(6): 1269–1274.CrossRefPubMedGoogle Scholar
  30. 30.
    Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006; 28(10): 1569–1581.CrossRefPubMedGoogle Scholar
  31. 31.
    Kolendorf K, Kim H. Lower risk of hypoglycemia at each level of glycemic control when insulin detemir is added to oral agents compared to NPH insulin in patients with type 2 diabetes. Diabetes 2005; 54:A121.Google Scholar
  32. 32.
    Fritsche A, Haring H. At last, a weight neutral insulin? Int J Obes Relat Metab Disord 2004; 28(Suppl. 2):S41–S46.CrossRefPubMedGoogle Scholar
  33. 33.
    Hordern SV, Wright JE, Umpleby AM, Shojaee-Moradie F, Amiss J, Russell-Jones DL. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia 2005; 48(3):420–426.CrossRefPubMedGoogle Scholar
  34. 34.
    Ceriello A, Davidson J, Hanefeld M, Leiter L, Monnier L, Owens D et al. Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. Nutr Metab Cardiovasc Dis 2006; 16(7):453–456.CrossRefPubMedGoogle Scholar
  35. 35.
    Hermansen K, Colombo M, Storgaard H, OStergaard A, Kolendorf K, Madsbad S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002; 25(5):883–888.CrossRefPubMedGoogle Scholar
  36. 36.
    Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med 2002;19(5):393–399.CrossRefPubMedGoogle Scholar
  37. 37.
    Boehm BO, Vaz JA, Brondsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med 2004; 15(8):496–502.CrossRefPubMedGoogle Scholar
  38. 38.
    Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care 1999;22(8):1258–1261.CrossRefPubMedGoogle Scholar
  39. 39.
    McNally PG, Nelson G, Fitch M. Patients with Type 2 diabetes mellitus have lower rates of nocturnal hypoglycaemia on biphasic insulin aspart (BIAsp30) than on biphasic human insulin-30 (BHI30): data from the REACH study. Diabetologia 2004;47:A327.Google Scholar
  40. 40.
    Iwamoto Y. A randomised, multicentre trial of biphasic insulin aspart versus biphasic human insulin in Type 2 diabetes. Diabetologia 2003;46:A270.Google Scholar
  41. 41.
    Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006;114(9):527–532.CrossRefPubMedGoogle Scholar
  42. 42.
    Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1–2-3 study). Diabetes Obes Metab 2006;8(1):58–66.CrossRefPubMedGoogle Scholar
  43. 43.
    Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complicat 2003;17(6):307–313.CrossRefPubMedGoogle Scholar
  44. 44.
    Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26(3):881–885.CrossRefPubMedGoogle Scholar
  45. 45.
    Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005; 54(1):1–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7(1):56–64.CrossRefPubMedGoogle Scholar
  47. 47.
    Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66(2):193–201.CrossRefPubMedGoogle Scholar
  48. 48.
    Anderson JH, Jr., Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. Clin Ther 1997;19(1):62–72.CrossRefPubMedGoogle Scholar
  49. 49.
    Anderson JH, Jr., Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 1997; 157(11):1249–1255.CrossRefPubMedGoogle Scholar
  50. 50.
    Ross SA, Zinman B, Campos RV, Strack T. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med 2001;24(6):292–298.PubMedGoogle Scholar
  51. 51.
    Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27(10):2363–2368.CrossRefPubMedGoogle Scholar
  52. 52.
    Hermansen K. Waiting to inhale: noninjectable insulin, are we there yet? Curr Diab Rep 2004; 4(5):335–341.CrossRefPubMedGoogle Scholar
  53. 53.
    Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005;90(6):3287–3294.CrossRefPubMedGoogle Scholar
  54. 54.
    Rave K, Bott S, Heinemann L, Sha S, Becker RH, Willavize SA et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005;28(5):1077–1082.CrossRefPubMedGoogle Scholar
  55. 55.
    Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28(11): 2673–2679.CrossRefPubMedGoogle Scholar
  56. 56.
    Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999;46(3):239–246.CrossRefPubMedGoogle Scholar
  57. 57.
    Freemantle N, Blonde L, Duhot D, Hompesch M, Eggertsen R, Hobbs FD et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005;28(2):427–428.CrossRefPubMedGoogle Scholar
  58. 58.
    Weiss SR, Cheng SL, Kourides IA, Gelfand RA, Landschulz WH. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med 2003; 163(19):2277–2282.CrossRefPubMedGoogle Scholar
  59. 59.
    Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005;143(8):549–558.PubMedGoogle Scholar
  60. 60.
    Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004;27(10):2356–2362.CrossRefPubMedGoogle Scholar
  61. 61.
    DeFronzo RA, Bergenstal RM, Cefalu WT, Pullman J, Lerman S, Bode BW et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005; 28(8):1922–1928.CrossRefPubMedGoogle Scholar
  62. 62.
    Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Diabetes Care 2006; 29(8):1818–1825.CrossRefPubMedGoogle Scholar
  63. 63.
    Goudswaard AN FNVGSRRG. Insulin montherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes (review). 1–52. 2004. Cochrane Database Systematic Reviews 2004, Issue 4.Art NO.:CD003418.DOI: 10.1002/14651858.CD003418.pub2.Google Scholar
  64. 64.
    Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24(4): 758–767.CrossRefPubMedGoogle Scholar
  65. 65.
    Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27(7):1535–1540.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Sten Madsbad
    • 1
  1. 1.Department of Endocrinology, Hvidovre HospitalUniversity of CopenhagenDenmark

Personalised recommendations